1. Krishnaveni, G., S. Wagle, and C. Yajnik, Intrauterine malnutrition and future risk of metabolic syndrome, in Metabolic Syndrome. 2024, Elsevier. p. 21-34.
2. Satpathi, T., R. Unnikrishnan, and V. Mohan, Intervening at the stage of metabolic syndrome to prevent type 2 diabetes—Is it justified?, in Metabolic Syndrome. 2024, Elsevier. p. 35-43.
3. Burrage, L. and A. Sinha, Understanding the complexities of metabolic syndrome in First Nations Australians, in Metabolic Syndrome. 2024, Elsevier. p. 93-103.
4. Dong, S., et al., Metabolic syndrome and breast cancer: prevalence, treatment response, and prognosis. Frontiers in oncology, 2021. 11: p. 629666.
5. Belhayara, M.I., et al., The metabolic syndrome: emerging novel insights regarding the relationship between the homeostasis model assessment of insulin resistance and other key predictive markers in young adults of Western Algeria. Nutrients, 2020. 12(3): p. 727.
6. Jha, B.K., et al., Progress in Understanding Metabolic Syndrome and Knowledge of Its Complex Pathophysiology. Diabetology, 2023. 4(2): p. 134-159.
7. Desroches, S. and B. Lamarche, The evolving definitions and increasing prevalence of the metabolic syndrome. Applied Physiology, Nutrition, and Metabolism, 2007. 32(1): p. 23-32.
8. Tian, Y., G. Jing, and M. Zhang, Insulin-degrading enzyme: roles and pathways in ameliorating cognitive impairment associated with Alzheimer’s disease and diabetes. Ageing Research Reviews, 2023: p. 101999.
9. Leissring, M.A., et al., Targeting insulin-degrading enzyme in insulin clearance. International journal of molecular sciences, 2021. 22(5): p. 2235.
10. González-Casimiro, C.M., et al., Modulation of insulin sensitivity by insulin-degrading enzyme. Biomedicines, 2021. 9(1): p. 86.
11. Pivovarova, O., et al., Insulin-degrading enzyme: new therapeutic target for diabetes and Alzheimer’s disease? Annals of medicine, 2016. 48(8): p. 614-624.
12. Lesire, L., et al., Insulin-Degrading Enzyme, an Under-Estimated Potential Target to Treat Cancer? Cells, 2022. 11(7): p. 1228.
13. Binayi, F., et al., Sustained feeding of a diet high in fat resulted in a decline in the liver’s insulin-degrading enzyme levels in association with the induction of oxidative and endoplasmic reticulum stress in adult male rats: evaluation of 4-phenylbutyric acid. Heliyon, 2024.
14. Najjar, S.M. and G. Perdomo, Hepatic insulin clearance: mechanism and physiology. Physiology, 2019. 34(3): p. 198-215.
15. Organization, W.H., Waist circumference and waist-hip ratio: report of a WHO expert consultation, Geneva, 8-11 December 2008. 2011.
16. Mohajan, D. and H.K. Mohajan, Body mass index (BMI) is a popular anthropometric tool to measure obesity among adults. Journal of Innovations in Medical Research, 2023. 2(4): p. 25-33.
17. ELABSCIENCE. Human IDE(Insulin Degrading Enzyme) ELISA Kit. Available at: https://www.elabscience.com/p-human_ide_insulin_degrading_enzyme_elisa_kit-18196.html. 2023.
18. Burtis, C.A. and E.R. Ashwood, Tietz textbook of clinical chemistry. Philadelphia, 1999. 1999: p. 1654-5.
19. Rifai, N., P.S. Bachorik, and J.J. Albers, Lipids, lipoproteins and apolipoproteins. Tietz textbook of clinical chemistry, 1999. 3: p. 809-861.
20. Kula, S.B., Evaluation of Enzymatic Sarcosine Oxidase Method and Comparison with Modified Kinetic Jaffe’s Reaction Analytical Method for Quantitative Analysis of Creatinine. 2022, JKUAT-COHES.
21. Thomas, L., Clinical Laboratory Diagnostics. 1st ed. Frankfurt: TH-Books Verlagsgesellschaft Vol. 2. 1998.
22. SEKISUI MEDICAL CO., L. NORUDIA Isulin. Retrieved from SEKISUI MEDICAL CO., LTD.

. 2017; Available from: international@sekisui.com.

23. Hansson, L.-O. and L. Lindquist, C-reactive protein: its role in the diagnosis and follow-up of infectious diseases. Current Opinion in infectious diseases, 1997. 10(3): p. 196-201.
24. Jagesh, R., et al., Impact of Adoption of Directly Measured Low-Density Lipoprotein-Cholesterol (LDL-C) on Targets of Lipid Control and Its Comparison With Friedewald Formula-Calculated LDL Cholesterol in People With Type-2 Diabetes Mellitus. Indian Journal of Clinical Cardiology, 2021. 2(3): p. 135-141.
25. Wallace, T.M., J.C. Levy, and D.R. Matthews, Use and abuse of HOMA modeling. Diabetes care, 2004. 27(6): p. 1487-1495.
26. Adams-Huet, B. and I. Jialal, Correlates of insulin resistance in nascent metabolic syndrome. Clinical Medicine Insights: Endocrinology and Diabetes, 2023. 16: p. 11795514231168279.
27. Carmen Zaha, D., et al., Influence of inflammation and adipocyte biochemical markers on the components of metabolic syndrome. Experimental and therapeutic medicine, 2020. 20(1): p. 121-128.
28. Maleki, A., et al., Metabolic syndrome and inflammatory biomarkers in adults: a population-based survey in Western region of Iran. International cardiovascular research journal, 2014. 8(4): p. 156.
29. Masenga, S.K., et al., Mechanisms of oxidative stress in metabolic syndrome. International journal of molecular sciences, 2023. 24(9): p. 7898.
30. Katsimardou, A., et al., Hypertension in metabolic syndrome: novel insights. Current hypertension reviews, 2020. 16(1): p. 12-18.
31. Kotsis, V., et al., Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part B: obesity-induced cardiovascular disease, early prevention strategies and future research directions. Journal of hypertension, 2018. 36(7): p. 1441-1455.
32. Mancia, G., et al., The sympathetic nervous system and the metabolic syndrome. Journal of hypertension, 2007. 25(5): p. 909-920.
33. Schlaich, M., et al., Metabolic syndrome: a sympathetic disease? The lancet Diabetes & endocrinology, 2015. 3(2): p. 148-157.
34. Kotsis, V., et al., Mechanisms of obesity-induced hypertension. Hypertension research, 2010. 33(5): p. 386-393.
35. Sofer, Y., et al., Insulin-degrading enzyme higher in subjects with metabolic syndrome. Endocrine, 2021. 71: p. 357-364.
36. Lau, C.-H. and S. Muniandy, Novel adiponectin-resistin (AR) and insulin resistance (IR AR) indexes are useful integrated diagnostic biomarkers for insulin resistance, type 2 diabetes and metabolic syndrome: a case control study. Cardiovascular diabetology, 2011. 10: p. 1-18.
37. Galicia-Garcia, U., et al., Pathophysiology of type 2 diabetes mellitus. International journal of molecular sciences, 2020. 21(17): p. 6275.
38. Alexander, C.M., et al., NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes, 2003. 52(5): p. 1210-1214.
39. Klop, B., J.W.F. Elte, and M. Castro Cabezas, Dyslipidemia in obesity: mechanisms and potential targets. Nutrients, 2013. 5(4): p. 1218-1240.
40. Jung, U.J. and M.-S. Choi, Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. International journal of molecular sciences, 2014. 15(4): p. 6184-6223.
41. Welty, F.K., A. Alfaddagh, and T.K. Elajami, Targeting inflammation in metabolic syndrome. Translational research, 2016. 167(1): p. 257-280.
42. Dallmeier, D., et al., Metabolic syndrome and inflammatory biomarkers: a community-based cross-sectional study at the Framingham Heart Study. Diabetology & metabolic syndrome, 2012. 4(1): p. 28.
43. Festa, A., et al., Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation, 2000. 102(1): p. 42-47.
44. De Feo, P., et al., Physiological increments in plasma insulin concentrations have selective and different effects on synthesis of hepatic proteins in normal humans. Diabetes, 1993. 42(7): p. 995-1002.
45. Farris, W., et al., Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo. Proceedings of the National Academy of Sciences, 2003. 100(7): p. 4162-4167.
46. Abdul-Hay, S.O., et al., Deletion of insulin-degrading enzyme elicits antipodal, age-dependent effects on glucose and insulin tolerance. PloS one, 2011. 6(6): p. e20818.
47. Villa-Pérez, P., et al., Liver-specific ablation of insulin-degrading enzyme causes hepatic insulin resistance and glucose intolerance, without affecting insulin clearance in mice. Metabolism, 2018. 88: p. 1-11.
48. Sousa, L., et al., Insulin‐degrading enzyme: an ally against metabolic and neurodegenerative diseases. The Journal of pathology, 2021. 255(4): p. 346-361.
49. Borges, D.O., et al., Loss of postprandial insulin clearance control by Insulin-degrading enzyme drives dysmetabolism traits. Metabolism, 2021. 118: p. 154735.
50. Merino, B., et al., Hepatic insulin-degrading enzyme regulates glucose and insulin homeostasis in diet-induced obese mice. Metabolism, 2020. 113: p. 154352.